SYK Share Price | Stryker Corp. Stock Analysis & Recommendation

Q: How big is Stryker Corp.?

As of Jun 18, Stryker Corp. has a market capitalization of 142,688.90 million, classifying it as a Large Cap company.As of Jun 18, the company's net sales for the latest four quarters amount to 23,218.00 million, while the net profit for the same period is 2,859.00 million.As of Dec 24, the reporting period shows shareholder's funds at 20,634.00 million and total assets at 42,971.00 million.

Q: What does Stryker Corp. do?

Overview: Stryker Corporation is a medical technology company that operates in the Pharmaceuticals & Biotechnology industry, specializing in a range of medical technologies.Financial Snapshot: Net Sales: 5,866 Million (Quarterly Results - Mar 2025) Net Profit: 654 Million (Quarterly Results - Mar 2025) Market cap: USD 142,688.90 Million (Large Cap)Key Metrics: P/E: 34.00 Dividend Yield: 0.87% Debt Equity: 0.69 Return on Equity: 20.53% Price to Book: 6.82Contact Details: Address: 2825 Airview Blvd, PORTAGE MI: 49002-1802 Tel: 1 269 3892600 Website: https://www.stryker.com/

Q: Who are in the management team of Stryker Corp.?

As of March 2022, the management team of Stryker Corp. includes the following members:- Mr. Kevin Lobo, who serves as the Chairman of the Board and Chief Executive Officer.- Mr. Allan Golston, who is the Lead Independent Director.- Dr. Giovanni Caforio, who is a Director.- Ms. Mary Brainerd, who serves as an Independent Director.- Dr. Srikant Datar, who is also an Independent Director.- Dr. Roch Doliveux, who is another Independent Director. This team plays a crucial role in guiding the company's strategic direction and governance.

Q: Is Stryker Corp. technically bullish or bearish?

As of 12 September 2025, the technical trend for Stryker Corp. has changed from sideways to mildly bearish. The current stance is mildly bearish, supported by weekly and monthly MACD readings, both indicating a bearish outlook. The KST and Dow Theory also reflect a mildly bearish trend on both time frames. Although the daily moving averages show a mildly bullish signal, this is overshadowed by the overall bearish indicators. The stock has underperformed compared to the S&P 500 over the past week and month, with returns of -2.82% and -0.99% respectively, while the S&P 500 gained 1.05% and 2.33%.

Q: Is Stryker Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Stryker Corp. has moved from very expensive to expensive, indicating a slight improvement but still suggesting that the stock is overvalued. The company is currently assessed as overvalued based on its P/E ratio of 34, which is significantly higher than the industry average, and an EV to EBITDA ratio of 25.94, also above typical industry levels. Additionally, the PEG ratio stands at 1.86, suggesting that the stock may not be justified at its current price given its growth prospects.In comparison to its peers, Abbott Laboratories has a P/E of 18.36, while Medtronic Plc shows a P/E of 21.47, both indicating that Stryker is trading at a premium relative to these companies. Notably, Stryker's recent stock performance has lagged behind the S&P 500, with a year-to-date return of 3.99% compared to the S&P 500's 13.30%, and a three-year return of 73.64% versus 81.19% for the index. This underperformance reinforces the notion that Stryker Corp. is overvalued in the current market environment.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.77 M

Shareholding (Dec 2025)

FII

19.22%

Held by 560 FIIs

DII

54.14%

Held by 61 DIIs

Promoter

0.18%

How big is Stryker Corp.?

22-Jun-2025

As of Jun 18, Stryker Corp. has a market capitalization of $142.69 billion, with net sales of $23.22 billion and a net profit of $2.86 billion over the latest four quarters.

View full answer

What does Stryker Corp. do?

22-Jun-2025

Stryker Corporation is a medical technology company specializing in various medical technologies, with a market cap of approximately $142.69 billion and a net profit of $654 million as of March 2025. Key metrics include a P/E ratio of 34.00 and a dividend yield of 0.87%.

View full answer

Who are in the management team of Stryker Corp.?

22-Jun-2025

As of March 2022, Stryker Corp.'s management team includes Chairman and CEO Kevin Lobo, Lead Independent Director Allan Golston, and Independent Directors Mary Brainerd, Srikant Datar, and Roch Doliveux, along with Director Giovanni Caforio. They are responsible for the company's strategic direction and governance.

View full answer

Is Stryker Corp. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Stryker Corp. is in a mildly bearish trend, indicated by bearish MACD readings and underperformance against the S&P 500, despite some daily moving averages showing mild bullishness.

View full answer

Is Stryker Corp. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Stryker Corp. is considered overvalued with a P/E ratio of 34, an EV to EBITDA ratio of 25.94, and a PEG ratio of 1.86, indicating it trades at a premium compared to peers like Abbott Laboratories and Medtronic, while also underperforming the S&P 500.

View full answer

Compare Stryker Corp. with Similar Stocks

Danaher Corp.Abbott Laboratories Thermo Fisher Scientific, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Company has very low debt and has enough cash to service the debt requirements

Flat results in Jun 25

With ROCE of 14.53%, it has a very expensive valuation with a 4.55 Enterprise value to Capital Employed

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 145,510 Million (Large Cap)

P/E

32.00

Industry P/E

Dividend Yield

0.89%

Debt Equity

0.53

Return on Equity

17.83%

Price to Book

6.49

Revenue and Profits:

Net Sales:

7,171 Million

(Quarterly Results - Dec 2025)

Net Profit:

849 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

4.47%

6 Months

-2.41%

1 Year

0.51%

2 Years

8.37%

3 Years

46.09%

4 Years

51.7%

5 Years

56.04%

Stryker Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

11.84%

EBIT Growth (5y)

14.94%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

2.44

Net Debt to Equity (avg)

0.69

Sales to Capital Employed (avg)

0.64

Tax Ratio

14.22%

Dividend Payout Ratio

40.48%

Pledged Shares

Institutional Holding

80.69%

ROCE (avg)

13.69%

ROE (avg)

18.82%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

6.88

EV to EBIT

29.57

EV to EBITDA

24.58

EV to Capital Employed

4.51

EV to Sales

6.72

PEG Ratio

1.48

Dividend Yield

0.88%

ROCE (Latest)

15.26%

ROE (Latest)

21.38%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 203 Schemes (26.43%)

Foreign Institutions

Held by 560 Foreign Institutions (19.22%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 11.42% vs 10.68% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 55.49% vs -52.23% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7,171.00",
          "val2": "6,436.00",
          "chgp": "11.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,305.00",
          "val2": "2,045.00",
          "chgp": "12.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "154.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-180.00",
          "val2": "-1,182.00",
          "chgp": "84.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "849.00",
          "val2": "546.00",
          "chgp": "55.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "277.40%",
          "val2": "276.70%",
          "chgp": "0.07%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 11.16% vs 10.23% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 8.45% vs -5.43% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "25,116.00",
          "val2": "22,595.00",
          "chgp": "11.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7,039.00",
          "val2": "6,173.00",
          "chgp": "14.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "607.00",
          "val2": "396.00",
          "chgp": "53.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-907.00",
          "val2": "-1,359.00",
          "chgp": "33.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3,246.00",
          "val2": "2,993.00",
          "chgp": "8.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "232.80%",
          "val2": "226.70%",
          "chgp": "0.61%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

7,171.00

6,436.00

11.42%

Operating Profit (PBDIT) excl Other Income

2,305.00

2,045.00

12.71%

Interest

154.00

0.00

Exceptional Items

-180.00

-1,182.00

84.77%

Consolidate Net Profit

849.00

546.00

55.49%

Operating Profit Margin (Excl OI)

277.40%

276.70%

0.07%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 11.42% vs 10.68% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 55.49% vs -52.23% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

25,116.00

22,595.00

11.16%

Operating Profit (PBDIT) excl Other Income

7,039.00

6,173.00

14.03%

Interest

607.00

396.00

53.28%

Exceptional Items

-907.00

-1,359.00

33.26%

Consolidate Net Profit

3,246.00

2,993.00

8.45%

Operating Profit Margin (Excl OI)

232.80%

226.70%

0.61%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 11.16% vs 10.23% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 8.45% vs -5.43% in Dec 2024

All Annual Results

Company CV

About Stryker Corp.

Stryker Corp.

Pharmaceuticals & Biotechnology

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. Its segments include Orthopaedics, MedSurg, Neurotechnology and Spine. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. Its products include implants, which are used in joint replacement and trauma surgeries, and other products. It offers musculoskeletal care and sensor technology for total joint replacement.

Company Coordinates

Company Details

2825 Airview Blvd , PORTAGE MI : 49002-1802

Tel: 1 269 3892600

https://www.stryker.com/

Registrar Details